Elutia (NASDAQ:ELUT – Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, November 14th.
Elutia Price Performance
NASDAQ ELUT opened at $3.80 on Tuesday. The firm has a market cap of $129.43 million, a P/E ratio of -1.33 and a beta of 0.76. The company’s 50 day moving average is $3.76 and its 200-day moving average is $3.67. Elutia has a 12-month low of $1.39 and a 12-month high of $5.24.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price objective on shares of Elutia in a research report on Friday, September 6th.
Elutia Company Profile
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
- Five stocks we like better than Elutia
- Financial Services Stocks Investing
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- How to Use Stock Screeners to Find Stocks
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- These 3 Active ETFs Beat the S&P 500 Over the Last Five Years
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
